G-CSF prophylaxis is also advised for patients with MM who have additional risk factors (e.g. those aged > 65 years, frail patients and patients with comorbidities) who are receiving a regimen associated with an intermediate risk of neutropenia (e.g. triplet regimens containing bortezomib) [8]. This evidence concerns the gene CSF3 and neutropenia.